BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 2827690)

  • 1. [Kinetic properties and regulation of cyclic nucleotide phosphodiesterases in lymphoid cells].
    Azhaeva EV; Severin ES
    Bioorg Khim; 1987 Sep; 13(9):1157-63. PubMed ID: 2827690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissimilar cyclic nucleotide phosphodiesterase activities in subcellular fractions from normal and SV40-transformed WI-38 fibroblasts.
    Nemecek GM; Butcher RW
    J Cyclic Nucleotide Res; 1979 Dec; 5(6):449-61. PubMed ID: 94064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [cGMP-dependent cyclic nucleotide phosphodiesterase from human lymphoid cells].
    Azhaeva EV; Severin SE; Kondrat'ev AD
    Biokhimiia; 1987 Nov; 52(11):1781-5. PubMed ID: 2830912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggregation states of cyclic nucleotide phosphodiesterase of murine thymocytes.
    Sobolev AS; Rybalkin SD
    Cell Biochem Funct; 1986 Jul; 4(3):205-11. PubMed ID: 3015450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phosphodiesterases of cyclic GMP].
    Wróblewska H; Gorczyca WA
    Postepy Hig Med Dosw; 2001; 55(5):611-27. PubMed ID: 11795198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterase of normal and leukemic lymphocytes. Kinetic properties and selective alteration of the activity of the multiple molecular forms.
    Hait WN; Weiss B
    Mol Pharmacol; 1979 Nov; 16(3):851-64. PubMed ID: 231197
    [No Abstract]   [Full Text] [Related]  

  • 8. [The process of cyclic adenosine-3',5'-monophosphate phosphodiesterase activation by 2',5'-oligoadenylate].
    Tunitskaia VL; Itkes AV; Kochetkova MN; Severin ES
    Biokhimiia; 1983 Oct; 48(10):1721-5. PubMed ID: 6315087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
    Medvedeva MV
    Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative kinetic study of bovine calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes utilizing cAMP, cGMP and their 2'-O-anthraniloyl-,2'-O-(N-methylanthraniloyl)-derivatives as substrates.
    Grewal J; Karuppiah N; Mutus B
    Biochem Int; 1989 Dec; 19(6):1287-95. PubMed ID: 2561449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential susceptibility to biological detergents of the particulate cGMP-stimulated phosphodiesterase from rat heart: preservation of the allosteric properties of the solubilized enzyme.
    Timouyasse L; Prigent AF; Némoz G; Lagarde M; Pachéco H
    Biochem Int; 1989 Aug; 19(2):287-99. PubMed ID: 2554908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cyclic AMP-specific nucleotide phosphodiesterase from the insoluble fraction of the human brain].
    Kireeva NN; Bobruskin ID; Severin SE
    Biokhimiia; 1995 May; 60(5):694-708. PubMed ID: 7662796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
    Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
    J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic nucleotide derivatives as probes of phosphodiesterase catalytic and regulatory sites.
    Erneux C; Couchie D; Dumont JE; Jastorff B
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():107-18. PubMed ID: 6326517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of human lymphocyte high affinity cyclic AMP phosphodiesterase by culture with 1-methyl-3-isobutylxanthine.
    Thompson WJ; Ross CP; Hersh EM; Epstein PM; Strada SJ
    J Cyclic Nucleotide Res; 1980; 6(1):25-36. PubMed ID: 6155390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic nucleotide phosphodiesterase activity in patients with obstructive airways disease.
    Polson JB; Krzanowski JJ; Goldman AL; Szentivanyi A
    Allergol Immunopathol (Madr); 1982; 10(2):101-4. PubMed ID: 6125092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cyclic nucleotide phosphodiesterase activity associated with proliferation and cancer in human and murine lymphoid cells.
    Epstein PM; Mills JS; Ross CP; Strada SJ; Hersh EM; Thompson WJ
    Cancer Res; 1977 Nov; 37(11):4016-23. PubMed ID: 198126
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts.
    Epstein PM; Hachisu R
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():303-24. PubMed ID: 6202124
    [No Abstract]   [Full Text] [Related]  

  • 20. Proteolytic activation of Ca2+-dependent cyclic nucleotide phosphodiesterase from Escherichia coli.
    Iwasa Y
    Horm Metab Res; 1981 Jul; 13(7):414-5. PubMed ID: 6268507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.